These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26801327)

  • 1. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling.
    Fung EK; Cheal SM; Fareedy SB; Punzalan B; Beylergil V; Amir J; Chalasani S; Weber WA; Spratt DE; Veach DR; Bander NH; Larson SM; Zanzonico PB; Osborne JR
    EJNMMI Res; 2016 Dec; 6(1):7. PubMed ID: 26801327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.
    Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
    Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
    J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.
    Osborne JR; Green DA; Spratt DE; Lyashchenko S; Fareedy SB; Robinson BD; Beattie BJ; Jain M; Lewis JS; Christos P; Larson SM; Bander NH; Scherr DS
    J Urol; 2014 May; 191(5):1439-45. PubMed ID: 24135437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.
    Bandekar A; Zhu C; Jindal R; Bruchertseifer F; Morgenstern A; Sofou S
    J Nucl Med; 2014 Jan; 55(1):107-14. PubMed ID: 24337602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
    Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
    Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
    Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ImmunoPET of Malignant and Normal B Cells with
    Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
    Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
    [No Abstract]   [Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-Targeting Ability of Novel Anti-Prostate-Specific Membrane Antigen Antibodies.
    Hsieh HH; Kuo WY; Lin JJ; Chen HS; Hsu HJ; Wu CY
    ACS Omega; 2022 Sep; 7(35):31529-31537. PubMed ID: 36092556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models.
    Bouvet V; Wuest M; Jans HS; Janzen N; Genady AR; Valliant JF; Benard F; Wuest F
    EJNMMI Res; 2016 Dec; 6(1):40. PubMed ID: 27142881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.
    Pandit-Taskar N; O'Donoghue JA; Divgi CR; Wills EA; Schwartz L; Gönen M; Smith-Jones P; Bander NH; Scher HI; Larson SM; Morris MJ
    EJNMMI Res; 2015; 5():28. PubMed ID: 25984435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
    Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
    Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
    Tagawa ST; Vallabhajosula S; Christos PJ; Jhanwar YS; Batra JS; Lam L; Osborne J; Beltran H; Molina AM; Goldsmith SJ; Bander NH; Nanus DM
    Cancer; 2019 Aug; 125(15):2561-2569. PubMed ID: 31012963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.